Team also named Best in Show for Overall Excellence in Programmatic Media Award

For the second consecutive year, the Bayer Consumer Health Media Team has been selected as the winner in the Best In-House Media Operations category during the 2021 AdExchanger Awards. The team also earned Best In Show for Overall Excellence in Programmatic Media. The AdExchanger Awards celebrate excellence in digital marketing and advertising.

“Our in-house approach harnesses the power and passion of our employees as no one knows our business and brands better than the people who work at Bayer,” said Jeff Rasp, Head of Media, Digital Platforms and Content, Bayer Consumer Health. “As a result, our team is able to move more quickly and efficiently to seamlessly deliver creative and impactful media plans.”

Bayer Consumer Health began its journey of in-sourcing digital media strategy and operations in 2018. In 2019, the team was named a finalist by AdExchanger for Best In-House Media Operations.

“Our greatest achievement over the last few years has been building a second-to-none team of industry leading experts who work together seamlessly and bring out the best in each other,” said Jeff Jarrett, Chief Marketing Officer, Bayer Consumer Health. “Through their relentless pursuit of excellence, they are driving our business forward with their bold strategies and executions.”

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.us.

Bayer® and the Bayer Cross® are registered trademarks of Bayer.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005797/en/